Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. (AGIO) Healthcare & Pipeline Overview

Agios Pharmaceuticals, Inc. is a biopharmaceutical company specializing in cellular metabolism and related biology, offering PYRUKYND (mitapivat) for hemolytic anemias. With a focus on innovative medicines, Agios competes in the biotechnology sector alongside companies like ImmunityBio and Cogent Biosciences.

What Is the Investment Thesis for AGIO?

Agios Pharmaceuticals presents an investment opportunity centered on its focus in cellular metabolism and the commercial potential of PYRUKYND. With a market capitalization of $2.24B, Agios operates in the biotechnology sector, characterized by high growth and innovation. The company's gross margin stands at 82.1%, indicating strong pricing power and efficient production. Key growth catalysts include the expansion of PYRUKYND's indications and the advancement of AG-946 through clinical trials. However, the company's negative profit margin of -639.8% highlights the risks associated with high R&D expenses and the uncertainty of drug development. Investors should monitor clinical trial outcomes, regulatory approvals, and market adoption rates to assess the long-term value of Agios.

Based on FMP financials and quantitative analysis

AGIO Key Highlights

• Market Cap of $2.24B reflects investor valuation of Agios's pipeline and commercialized product.
• Gross Margin of 82.1% indicates strong pricing power for PYRUKYND.
• Profit Margin of -639.8% highlights significant R&D investment and operational losses.
• PYRUKYND (mitapivat) is approved for the treatment of hemolytic anemias, providing a revenue stream.
• AG-946 is in Phase I clinical study, representing potential future growth.

Who Are AGIO's Competitors?

AGIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGIO's Key Strengths?

• Approved product (PYRUKYND) generating revenue.
• Strong expertise in cellular metabolism.
• Innovative drug development platform.
• Experienced management team.

What Are AGIO's Weaknesses?

• High R&D expenses leading to negative profit margins.
• Reliance on a limited number of products.
• Dependence on regulatory approvals.
• Competition from larger pharmaceutical companies.

What Could Drive AGIO Stock Higher?

• Clinical trial results for AG-946 in Phase I study for hemolytic anemias.
• Expansion of PYRUKYND's market reach and adoption.
• Potential partnerships and collaborations to enhance R&D capabilities.

What Are the Key Risks for AGIO?

• Negative return on equity (-34.1%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory setbacks and delays in drug approvals.
• Competition from biosimilars and other therapies.
• High R&D expenses impacting profitability.
• Dependence on the success of PYRUKYND.

What Are the Growth Opportunities for AGIO?

• Expanding PYRUKYND's Indications: Agios has the opportunity to expand the approved indications for PYRUKYND beyond hemolytic anemias. Exploring its efficacy in other related hematological disorders could significantly increase its market reach. The market for hematological disorder treatments is projected to reach $40 billion by 2030, offering a substantial growth avenue for Agios. Successful clinical trials and regulatory approvals for new indications would be key to realizing this potential.
• Advancing AG-946 Through Clinical Trials: AG-946, currently in Phase I clinical study, represents a significant growth opportunity for Agios. Positive results from clinical trials could lead to regulatory approval and commercialization, providing a new revenue stream. The market for hemolytic anemia treatments is growing, driven by advancements in diagnostic techniques and increasing awareness. Successfully navigating the clinical trial process and securing regulatory approval are critical milestones for this growth driver.
• Strategic Partnerships and Collaborations: Agios can pursue strategic partnerships and collaborations with other pharmaceutical companies to expand its research and development capabilities. Collaborating on new drug candidates or therapeutic areas can reduce risk and accelerate innovation. The biotechnology industry is characterized by collaborations, with deals often involving upfront payments, milestone payments, and royalties. Successful partnerships can provide Agios with access to new technologies and markets.
• Geographic Expansion: Agios has the opportunity to expand its geographic presence beyond its current markets. Entering new regions, particularly in Asia and Europe, can increase its customer base and revenue. The global market for pharmaceuticals is growing, driven by increasing healthcare expenditure and aging populations. Successfully navigating regulatory requirements and establishing distribution networks in new markets are essential for this growth strategy.
• Acquisition of Complementary Assets: Agios can consider acquiring companies or assets that complement its existing pipeline and expertise. Acquiring technologies or drug candidates in related therapeutic areas can broaden its portfolio and reduce reliance on a single product. The biotechnology industry is characterized by M&A activity, with companies often acquiring smaller firms to gain access to innovative technologies. Successful acquisitions can provide Agios with new growth opportunities and synergies.

What Opportunities Does AGIO Have?

• Expanding indications for PYRUKYND.
• Advancing AG-946 through clinical trials.
• Strategic partnerships and collaborations.
• Geographic expansion into new markets.

What Threats Does AGIO Face?

• Regulatory setbacks and delays.
• Competition from biosimilars.
• Patent expirations.
• Economic downturn affecting healthcare spending.

What Are AGIO's Competitive Advantages?

• Proprietary drug development platform focused on cellular metabolism.
• Patent protection for PYRUKYND and other drug candidates.
• Established expertise in the treatment of hemolytic anemias.
• Strong relationships with key opinion leaders in the hematology field.

What Does AGIO Do?

Agios Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts. The company operates as a biopharmaceutical entity dedicated to the discovery and development of novel medicines, primarily targeting cellular metabolism and adjacent biological areas. Agios's primary focus is on creating treatments for diseases with unmet medical needs. Their lead product, PYRUKYND (mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, indicated for the treatment of hemolytic anemias. Additionally, Agios has AG-946, which is currently in Phase I clinical study, aimed at treating hemolytic anemias and potentially other indications. Agios is committed to advancing scientific understanding and translating it into effective therapies for patients. The company continues to invest in research and development to expand its pipeline and address a broader range of diseases related to cellular metabolism.

What Products and Services Does AGIO Offer?

• Discovers and develops medicines in the field of cellular metabolism.
• Offers PYRUKYND (mitapivat) for the treatment of hemolytic anemias.
• Conducts clinical trials for new drug candidates.
• Focuses on diseases with unmet medical needs.
• Engages in research and development activities.
• Seeks regulatory approvals for its products.

How Does AGIO Make Money?

• Develops and commercializes pharmaceutical products.
• Generates revenue through sales of PYRUKYND.
• Invests in research and development to expand its pipeline.
• Seeks partnerships and collaborations to enhance its capabilities.

What Industry Does AGIO Operate In?

Agios Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for treatments related to cellular metabolism is expanding, driven by advancements in genetic research and personalized medicine. Agios competes with companies like IBRX: ImmunityBio, Inc., COGT: Cogent Biosciences, Inc., and BEAM: Beam Therapeutics Inc., all focused on developing novel therapies. The industry is subject to stringent regulatory oversight, impacting the time and cost of bringing new drugs to market. Industry growth is fueled by increasing healthcare expenditure and demand for targeted therapies.

Who Are AGIO's Key Customers?

• Patients with hemolytic anemias.
• Healthcare providers who prescribe PYRUKYND.
• Hospitals and clinics that administer the drug.
• Pharmacies that dispense PYRUKYND.

Company Profile

Agios Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Brian Goff. AGIO has traded publicly since 2013.

Agios Pharmaceuticals, Inc. Financial Trajectory

Agios Pharmaceuticals, Inc. (AGIO) reported $20.7M in revenue for Q1 2026, reflecting 3.9% growth compared to the prior quarter. The company recorded a net loss of $99.1M, with diluted EPS of $-1.69. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, AGIO averaged $-1.81 in diluted EPS.

How Agios Pharmaceuticals, Inc. Is Valued

Agios Pharmaceuticals, Inc. carries a market capitalization of $2.24B, placing it in the mid-cap category. Relative to its peer group, AGIO's quantitative score of 23/100 is below the peer average of 73/100.

ROE -34%Key Financial Metrics

Return on equity for Agios Pharmaceuticals, Inc. stands at -34.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -23.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 14.19 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -25.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Agios Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 16.55 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Agios Pharmaceuticals, Inc. revenue of about $121.9M for fiscal 2026, with EPS near $-6.23. The estimate reflects 7 contributing analysts.

AGIO Financials

AGIO Latest News

AGIO Analyst Consensus

AGIO MoonshotScore

Common Questions About AGIO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources